Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel CAR-T with IL-15 in Hematological Malignancies
NCT06783816Phase 1Recruiting
- Sponsor
- Shanxi Bethune Hospital
- Start
- Dec 2023
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial in acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL) and multiple myeloma (MM), sponsored by Shanxi Bethune Hospital. Primary endpoints: Survival time of CAR-T in vivo at 6 months and Antitumor effects after reinfusion of CAR-T at 28 days. Started Dec 2023; status: recruiting.
02
Conditions
acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06783816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06783816.